Pemphigus. S2 Guideline for diagnosis and treatment - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV)
| Authors | |
|---|---|
| Year of publication | 2015 |
| Type | Article in Periodical |
| Magazine / Source | Journal of the European Academy of Dermatology and Venereology |
| MU Faculty or unit | |
| Citation | |
| Doi | http://dx.doi.org/10.1111/jdv.12772 |
| Field | Other medical specializations |
| Keywords | DOUBLE-BLIND TRIAL; MYCOPHENOLATE-MOFETIL; CLINICAL-TRIAL; SPARING AGENT; PULSE THERAPY; VULGARIS; RITUXIMAB; DEXAMETHASONE; AZATHIOPRINE; PLACEBO |
| Description | Background: Pemphigus encompasses a group of life-threatening autoimmune bullous diseases characterized by blisters and erosions of the mucous membranes and skin. Before the era of immunosuppressive treatment, the prognosis of pemphigus was almost fatal. Due to its rarity, only few prospective controlled therapeutic trials are available. Objectives:For this reason, a group of European dermatologists with a long-standing interest and expertise in basic and clinical pemphigus research has sought to define diagnostic and therapeutic guidelines for the management of patients with pemphigus. Results:This group identified the statements of major agreement or disagreement regarding the diagnostic and therapeutic management of pemphigus. The revised final version of the pemphigus guideline was finally passed on to the European Dermatology Forum (EDF) for a final consensus with the European Academy of Dermatology and Venereology (EADV) and the European Union of Medical Specialists (UEMS). |